JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Sarepta Therapeutics (NASDAQ:SRPT) Stock

Sarepta Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • JPMorgan raised its Sarepta price target from $20 to $22 but kept a neutral rating; the new target implies about 55% upside from the previous close.
  • Analyst opinion is mixed: ratings are evenly split among Buy, Hold, and Sell, while the consensus is Hold with a $23.80 price target.
  • Sarepta beat quarterly earnings and revenue expectations, reporting $0.13 per share and $381.35 million in revenue, though revenue fell 4.5% year over year.
  • Five stocks to consider instead of Sarepta Therapeutics.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) had its price target hoisted by equities researchers at JPMorgan Chase & Co. from $20.00 to $22.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has a "neutral" rating on the biotechnology company's stock. JPMorgan Chase & Co.'s target price points to a potential upside of 55.06% from the stock's previous close.

Other analysts also recently issued research reports about the stock. Royal Bank Of Canada boosted their price objective on shares of Sarepta Therapeutics from $17.00 to $18.00 and gave the company a "sector perform" rating in a report on Friday, November 6th. Weiss Ratings raised shares of Sarepta Therapeutics from a "sell (e+)" rating to a "sell (d)" rating in a report on Thursday, November 12th. Zacks Research downgraded shares of Sarepta Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Monday, October 5th. Needham & Company LLC reiterated an "underperform" rating on shares of Sarepta Therapeutics in a research note on Monday, September 28th. Finally, Deutsche Bank raised Sarepta Therapeutics from a "sell" rating to a "hold" rating and increased their price target for the stock from $14.00 to $18.00 in a research report on Tuesday, November 10th. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and six have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $23.80.

Read Our Latest Analysis on SRPT

Sarepta Therapeutics Stock Performance

NASDAQ SRPT traded down $0.34 on Thursday, reaching $14.19. The stock had a trading volume of 936,446 shares, compared to its average volume of 2,969,910. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.46 and a quick ratio of 2.13. The firm has a fifty day moving average of $18.17 and a two-hundred day moving average of $18.42. Sarepta Therapeutics has a 1-year low of $14.22 and a 1-year high of $24.68. The company has a market cap of $1.52 billion, a P/E ratio of -10.35, a price-to-earnings-growth ratio of 0.36 and a beta of 0.45.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its earnings results on Thursday, November 5th. The biotechnology company reported $0.13 earnings per share for the quarter, topping analysts' consensus estimates of $0.08 by $0.05. Sarepta Therapeutics had a negative return on equity of 0.20% and a negative net margin of 5.86%. The company had revenue of $381.35 million during the quarter, compared to the consensus estimate of $352.20 million. During the same quarter last year, the firm earned ($0.13) earnings per share. The company's revenue was down 4.5% on a year-over-year basis. On average, equities research analysts anticipate that Sarepta Therapeutics will post 3.15 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new stake in shares of Sarepta Therapeutics in the 3rd quarter valued at $182,000. Goldman Sachs Group Inc. raised its holdings in shares of Sarepta Therapeutics by 60.4% during the 3rd quarter. Goldman Sachs Group Inc. now owns 3,277,091 shares of the biotechnology company's stock worth $59,709,000 after buying an additional 1,234,590 shares in the last quarter. Empowered Funds LLC lifted its position in shares of Sarepta Therapeutics by 195.2% during the 3rd quarter. Empowered Funds LLC now owns 562,573 shares of the biotechnology company's stock worth $10,250,000 after buying an additional 371,987 shares during the last quarter. First Trust Advisors LP lifted its position in shares of Sarepta Therapeutics by 12.8% during the 3rd quarter. First Trust Advisors LP now owns 4,923,020 shares of the biotechnology company's stock worth $89,697,000 after buying an additional 557,069 shares during the last quarter. Finally, Advisors Asset Management Inc. acquired a new stake in Sarepta Therapeutics in the third quarter valued at about $87,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

About Sarepta Therapeutics

(Get Free Report)

Sarepta Therapeutics is a biotechnology company focused on developing genetic medicines for rare diseases, with an emphasis on Duchenne muscular dystrophy (DMD). Its research includes RNA-based treatments designed to affect how genetic instructions are processed, as well as gene therapy approaches. The company's DMD medicines include exon-skipping therapies such as eteplirsen (Exondys 51), golodirsen (Vyondys 53) and casimersen (Amondys 45). Each is intended for patients with a specific genetic mutation and works by helping cells produce a shortened form of dystrophin, a protein affected by DMD.

See Also

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Sarepta Therapeutics Right Now?

Before you consider Sarepta Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.

While Sarepta Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines